- |||||||||| Trial completion, Enrollment change: Topical Antibiotics in Chronic Rhinosinusitis (clinicaltrials.gov) - Apr 20, 2022
P1/2, N=19, Completed, There is no significant benefit of adding an oral antibiotic with the topical antibiotic steroid in the treatment of uncomplicated AOE limited to the ear canal in immunocompetent patients. Recruiting --> Completed | N=40 --> 19
- |||||||||| tobramycin topical / Generic mfg.
Clinical, Observational data, Journal: Off-label drug use in neonates and infants in Spain: a five-year observational study. (Pubmed Central) - Mar 26, 2022 Off-label use of drugs remains as an important public health concern, especially for neonates and infants up to 1 year, who receive the greatest proportion of off-label prescriptions. The evidence-based off-label prescription is a widespread practice that has shown a stable trend during the 5-year study period providing also a certain extent of flexibility to paediatricians in some therapeutic decisions.
- |||||||||| vancomycin / Generic mfg., tobramycin topical / Generic mfg.
Journal: Tobramycin Blood Levels after Local Antibiotic Treatment of Bone and Soft Tissue Infection. (Pubmed Central) - Mar 26, 2022 All systemic tobramycin levels were <2 mcg/mL at 72 h, and the resulting rate of AKI was 12% (7/58). In conclusion, local tobramycin antibiotic delivery using PMMA, CS, or both remains a safe and effective modality in the treatment of osteomyelitis as long as the surgeon is aware of its possible nephrotoxic effect.
- |||||||||| tobramycin topical / Generic mfg.
CHALLENGES IN THE MANAGEMENT OF FUNGAL KERATITIS – CASE REPORT (Track 1) - Feb 8, 2022 - Abstract #ESCRSWM2022ESCRS_WM_276; Microbial specimens were collected, and the patient started on topical ciprofloxacin ointment and tobramycin and ceftazidime eye drops...Fungus identification using microbiological techniques is essential for an early diagnosis, which allows the timely treatment and avoids irreversible complications. We report a case that documents the effectiveness of topical iodine povidone as an adjunctive treatment for refractory Fusarium keratitis, resistant to other triazoles and conventional antifungals.
- |||||||||| Zylet (loteprednol etabonate/tobramycin ophthalmic suspension) / Bausch Health
Review, Journal: Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis. (Pubmed Central) - Oct 30, 2021 Results of published studies indicate that LE/T is effective in the treatment of blepharokeratoconjunctivitis in adults, with similar efficacy as dexamethasone 0.1%/tobramycin 0.3%, but is associated with a lower risk of clinically significant increases in intraocular pressure as demonstrated in both efficacy and safety studies and studies with healthy volunteers...Separately, tobramycin demonstrated potent in vitro activity against most bacterial species associated with blepharitis. In conclusion, published data demonstrate the utility of LE/T for the treatment of the various clinical manifestations of blepharokeratoconjunctivitis in adults.
- |||||||||| vancomycin / Generic mfg., tobramycin topical / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures At High Risk of Infection: TOBRA (clinicaltrials.gov) - Jul 1, 2021 P3, N=1900, Recruiting, In conclusion, published data demonstrate the utility of LE/T for the treatment of the various clinical manifestations of blepharokeratoconjunctivitis in adults. Not yet recruiting --> Recruiting | Trial completion date: Dec 2022 --> May 2024 | Trial primary completion date: Dec 2022 --> May 2023
- |||||||||| Trial completion date, Trial primary completion date: Topical Antibiotics in Chronic Rhinosinusitis (clinicaltrials.gov) - Jan 8, 2021
P1/2, N=40, Recruiting, Initiation date: Mar 2021 --> Jun 2021 Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| Trial completion date, Trial primary completion date: Topical Antibiotics in Chronic Rhinosinusitis (clinicaltrials.gov) - Jan 3, 2020
P1/2, N=40, Recruiting, Initiation date: Oct 2020 --> Jan 2021 Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
- |||||||||| Trial completion date, Trial primary completion date: Topical Antibiotics in Chronic Rhinosinusitis (clinicaltrials.gov) - Aug 14, 2019
P1/2, N=40, Recruiting, Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Jul 2019 --> Dec 2019
- |||||||||| Enrollment open: Topical Antibiotics in Chronic Rhinosinusitis (clinicaltrials.gov) - Sep 26, 2018
P1/2, N=40, Recruiting, Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Jul 2019 --> Dec 2019 Not yet recruiting --> Recruiting
|